MedTrace Logo

Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer

NCT02635360 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2025-07-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will be administered after or during chemoradiation.

Conditions

Interventions

DRUG

Pembrolizumab

200 mg of study drug is given through intravenous (IV) administration once every 21 days for 3 months.

RADIATION

Brachytherapy

Radiation is done for standard clinical care purposes.

DRUG

Cisplatin

40 mg of chemotherapy drug will be given weekly for 5-6 weeks.

Sponsors & Collaborators

Principal Investigators

  • Linda Duska, MD · University of Virginia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-09
Primary Completion
2021-01-01
Completion
2022-12-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02635360 on ClinicalTrials.gov